Holen Sie sich die Stockscreener-App
59.12
0.77%
-0.46
Handel nachbörslich:
59.14
0.02
+0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$59.58
Offen:
$58.88
24-Stunden-Volumen:
9.25M
Relative Volume:
0.72
Marktkapitalisierung:
$120.77B
Einnahmen:
$48.48B
Nettoeinkommen (Verlust:
$7.27B
KGV:
16.59
EPS:
3.5626
Netto-Cashflow:
$11.91B
1W Leistung:
-3.32%
1M Leistung:
-8.21%
6M Leistung:
-0.59%
1J Leistung:
+32.32%
1-Tages-Spanne:
$58.74
$59.79
1-Wochen-Bereich:
$58.63
$60.10
52-Wochen-Spanne:
$42.52
$68.64
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.12 | 120.77B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-08-05 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - Zacks Investment Research
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors - GlobeNewswire Inc.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now? - Zacks Investment Research
2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One) - The Motley Fool
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward? - Zacks Investment Research
Can Redwire's Microgravity Pharma Work Create New Revenue Streams? - Zacks Investment Research
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Zacks Investment Research
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol-Myers Squibb: Patent Cliff Is Still A Problem (NYSE:BMY) - Seeking Alpha
Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA - Zacks Investment Research
Bristol-Myers Squibb Co (BMY) Shares Fall 3.8% -- GF Value Says Still Overvalued - GuruFocus
Bristol-Myers Squibb Co: Prelim Total Acquire - Moomoo
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.56% on Oct 5: What Investors Need To Know - TradingKey
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol Myers Squibb (BMY) withholds 2,332 shares for taxes as Cari Gallman's stock award vests. - Stock Titan
Bristol Myers Squibb Co. Research & Ratings | BMY - Barron's
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt - Investing.com
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt - Yahoo Finance
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now? - Zacks Investment Research
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement - Yahoo Finance
Bristol Myers Squibb Co. Research & Ratings | BMY - Barron's
Bristol-Myers Squibb (NYSE:BMY) Dividend Quality: High Yield, Sustainability Concerns - ChartMill
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? - The Motley Fool
CX Institutional Sells 208,135 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) director Arduini now holds 74,077 deferred stock units. - Stock Titan
After acquiring 620.994 deferred stock units, Rice holds 42,084.867 at Bristol Myers Squibb (BMY). - Stock Titan
Director Michael R. McMullen acquires 560.897 deferred stock units at Bristol Myers Squibb (BMY). - Stock Titan
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs - BioSpace
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Zacks Investment Research
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio? - TradingView
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale - The Globe and Mail
Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights - GlobeNewswire Inc.
Bristol Myers Squibb (BMY) Boosts Champions in Care Initiative w - gurufocus.com
Healthcare professionals can nominate nonprofits for Bristol Myers Squibb's $1 million grants - Stock Titan
Children with this heart condition have one FDA-approved option: Bristol Myers Squibb's CAMZYOS. - Stock Titan
FDA Approves Bristol Myers Squibb's Camzyos for Pediatric Obstru - gurufocus.com
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Zacks Investment Research
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block - BioSpace
Novo Nordisk Gives Uninspiring Outlook - The Motley Fool
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - Zacks Investment Research
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation - fool.com
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bristol Myers Squibb Co-Aktie (BMY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev |
Sep 09 '26 |
Sale |
64.57 |
6,249 |
403,498 |
18,748 |
| Massacesi Cristian | Officer |
Sep 09 '26 |
Proposed Sale |
64.57 |
6,249 |
403,498 |
0 |
| Short Bartie Wendy | EVP, Corporate Affairs |
Sep 01 '26 |
Option Exercise |
66.92 |
1,236 |
82,713 |
13,317 |
| Holzer Phil M | Officer |
Aug 25 '26 |
Proposed Sale |
67.50 |
500 |
33,750 |
0 |
| Holzer Phil M | SVP and Controller |
Aug 25 '26 |
Sale |
67.50 |
500 |
33,750 |
16,862 |
| Gallman Cari | EVP, General Counsel |
Aug 01 '26 |
Option Exercise |
0.00 |
1,061 |
0 |
14,192 |
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev |
Aug 01 '26 |
Option Exercise |
0.00 |
51,172 |
0 |
51,172 |
| Haller Julia A | Director |
Jun 15 '26 |
Option Exercise |
53.76 |
20,460 |
1,099,930 |
34,079 |
| Short Bartie Wendy | EVP, Corporate Affairs |
Jun 03 '26 |
Option Exercise |
0.00 |
8,040 |
0 |
15,957 |
| Lenkowsky Adam | EVP, Chief Commercial Officer |
May 01 '26 |
Option Exercise |
0.00 |
1,373 |
0 |
20,508 |
0.40%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):